Physician profile
Gregory Bell
NPI 1538117205
$634.50
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $254 · 2020: $210 · 2021: $148 · 2022: $23.28.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $183.21 | 2019-2020 | |
| Ucb, INC. | $79.58 | 2019-2021 | |
| Abbvie INC. | $67.60 | 2021-2022 | |
| Acorda Therapeutics, INC | $64.85 | 2019 | |
| Alexion Pharmaceuticals, INC. | $48.49 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $43.87 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $35.17 | 2021 | |
| Genzyme Corporation | $24.00 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $22.04 | 2021 | |
| Sk Life Science, INC. | $20.58 | 2021 | |
| Novartis Pharmaceuticals Corporation | $16.28 | 2019 | |
| Lilly USA, LLC | $16.23 | 2019 | |
| Greenwich Biosciences, INC. | $12.60 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.